NCT00620282View on ClinicalTrials.gov

The Effect of Liraglutide on Endothelial Function in Subjects With Type 2 Diabetes Mellitus

PHASE3CompletedINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

February 29, 2008

Primary Completion Date

May 31, 2010

Study Completion Date

May 31, 2010

Conditions
DiabetesDiabetes Mellitus, Type 2
Interventions
DRUG

liraglutide

Stepwise dose increase, s.c. (under the skin) injection, once daily

DRUG

placebo

Liraglutide placebo, stepwise dose increase, s.c. (under the skin) injection, once daily

DRUG

glimepiride

Tablets, 1 - 4 mg daily

Trial Locations (1)

55905

Novo Nordisk Investigational Site, Rochester

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY

NCT00620282 - The Effect of Liraglutide on Endothelial Function in Subjects With Type 2 Diabetes Mellitus | Biotech Hunter | Biotech Hunter